Athena Vale
Metformin is a common drug used to treat type 2 diabetes and has been found to have surprising applications on a cellular level. While it is known to induce muscle atrophy, it has also been found to reduce muscle atrophy and muscular fibrosis, particularly in the elderly, aiding faster recovery from injury or illness.
| Characteristics | Values |
|---|---|
| Potential to reduce skeletal muscle atrophy | Yes |
| Potential to promote the differentiation of muscle cells | Yes |
| Potential to increase muscle recovery following disuse in aging | Yes |
| Potential to reduce fibrosis or excessive collagen in muscles | Yes |
| Potential to increase myotube diameter | Yes |
| Potential to reduce expression levels of atrophy-marker proteins | Yes |
| Potential to increase expression levels of differentiation proteins MHC, MyoD, and myogenin | Yes |
| Potential to reduce muscle atrophy through the regulation of myostatin in skeletal muscle cells | Yes |
| Potential to increase the nuclear localization of FoxO3a | Yes |
| Potential to induce the binding of FoxO3a to the myostatin promoter | Yes |
| Potential to increase the expression of myostatin | Yes |
| Potential to trigger the phosphorylation of AMPK | Yes |
| Potential to alter histone deacetylase activity in muscle cells | Yes |
| Potential to increase skeletal muscle mitochondrial H2O2 emission and production | Yes |
Explore related products
What You'll Learn
Metformin's impact on muscle atrophy
Metformin is an important anti-diabetic drug that has been used in diabetes treatment for over half a century. It is commonly administered to patients with type 2 diabetes to decrease hepatic glucose production and intestinal absorption of glucose. However, long-term metformin administration is associated with side effects, one of which is muscle atrophy.
Several studies have demonstrated that metformin treatment impairs muscle function and induces muscle atrophy, particularly in skeletal muscle cells. This muscle-wasting effect is more evident in WT mice than in db/db mice, indicating that more complex mechanisms may be involved in metformin-mediated muscular dysfunction. The exact molecular mechanism of metformin in muscle is still unclear, but it is believed to be related to the up-regulation of atrophy-related genes and the enhancement of the ubiquitin proteasome system.
Metformin induces the expression of myostatin, a key molecule that regulates muscle volume and triggers the phosphorylation of AMPK. Myostatin plays a central role in the development and maintenance of skeletal muscle by acting as a negative regulator of muscle mass. Increased myostatin expression has been observed in various disease states, including type 2 diabetes and cancer. Insulin resistance and high blood glucose levels, which are common in patients with type 2 diabetes, accelerate the loss of muscle mass and quality associated with increased myostatin levels.
Despite the evidence of metformin's role in inducing muscle atrophy, some studies suggest that it may also have protective effects on muscle. For example, one study found that metformin treatment increased the expression levels of ZEB1, a transcription factor that inhibits muscle atrophy. Additionally, University of Utah Health researchers have discovered that metformin can target senescent cells, which accumulate with age and impact muscle function. In a study where healthy older adults underwent a period of bed rest, those who took metformin had less muscle atrophy and fibrosis during the recovery period.
Theraworks for Muscle Soreness: Does It Really Work?
You may want to see also
Explore related products
Metformin's role in muscle recovery
Metformin is a common drug that has been used in diabetes treatment for over half a century. It is a metabolic drug that can enhance muscle regeneration and stem cell function. It is recommended as a first-line oral therapy for type 2 diabetes, managing hyperglycemia by decreasing hepatic glucose production. Metformin also increases glucose uptake through the upregulation of the glucose transporter type 4 (GLUT4).
Several studies have demonstrated the protective effect of metformin in mitigating skeletal muscle damage and its modulation of stem cell function in the context of injury. For example, metformin treatment has been shown to attenuate muscle wasting in response to burn-induced skeletal muscle wasting. Metformin treatment has also been shown to increase the expression levels of ZEB1 and three differentiation proteins: MHC, MyoD, and myogenin.
In addition, metformin has anti-senescent properties. Senescent cells are "zombie-like cells" that impact muscle function, and their accumulation can slow down recovery from injury or illness. Metformin can target these senescent cells, reducing their number and helping to prevent muscle atrophy and muscular fibrosis. This can aid in faster recovery from injury or illness, particularly in the elderly.
While the exact molecular mechanism of metformin's role in muscle recovery is still unclear, studies suggest that it may be related to the transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), which participates in inhibiting muscle atrophy. Furthermore, metformin's ability to increase muscle progenitor cells and modulate muscle inflammation may also contribute to its role in muscle recovery.
Overall, metformin shows potential as a therapeutic drug for muscle recovery, especially in the context of injury, illness, and aging.
Muscle Recovery: Rapid Healing and Factors Affecting It
You may want to see also
Explore related products
Metformin's effect on muscle cells
Metformin is a common drug that has been used in diabetes treatment for over half a century. It is an important anti-diabetic drug and is the first-line and most widely prescribed medication for patients with type 2 diabetes. The drug helps to regulate blood sugar and can also prevent muscle atrophy and muscular fibrosis, which can aid the elderly in recovering from injury or illness more quickly.
On a cellular level, metformin targets senescent cells, which are "zombie-like cells" that impact muscle function. Senescent cells secrete factors associated with inflammation that may underlie fibrotic tissue, a hardening or scarring of tissues. Metformin's anti-senescent properties have been demonstrated through pre-clinical studies. In one study, participants who took metformin during bed rest experienced less muscle atrophy and less fibrosis during the recovery period. The research team examined muscle biopsies from the participants and found that those who took metformin had fewer markers of cellular senescence.
However, some studies have shown that metformin can also induce muscle atrophy. Metformin has been shown to induce the expression of myostatin, a key molecule that regulates muscle volume and triggers the phosphorylation of AMPK. This can result in a decrease in muscle fibre size and protein content, leading to a loss of muscle mass and quality. The muscle-wasting effect of metformin is more evident in wild-type mice than in db/db mice, indicating that more complicated mechanisms may be involved in metformin-mediated muscular dysfunction.
Overall, while metformin has been shown to have some beneficial effects on muscle cells, the exact molecular mechanism of its function remains unclear and further research is needed to fully understand its effects on muscle cells.
Training the Masseter Muscle: A Guide to Powerful Chews
You may want to see also
Explore related products
Metformin's influence on muscle fibrosis
Metformin is a widely used anti-diabetic drug that has been prescribed for over half a century. It is known to reduce blood sugar and is also being studied for its potential applications in non-diabetic diseases.
Recent studies have found that metformin can prevent muscle atrophy and muscular fibrosis, which can aid in faster recovery from injury or illness, particularly in the elderly. This is because metformin can target senescent cells, which are associated with inflammation and fibrotic tissue, a hardening or scarring of tissues.
In one study, participants who took metformin during a period of bed rest experienced less muscle atrophy and less fibrosis during the recovery period. Their muscles had reduced markers of cellular senescence, and the drug helped muscle cells remodel and repair tissue.
In addition, metformin has been found to improve symptoms of neuromuscular diseases, delay hypokinesia, and regulate skeletal muscle mass. It can also reduce peritoneal fibrosis by improving mitochondrial function and modulating the quality of mitochondria. Furthermore, metformin has been shown to reverse lung fibrosis by inhibiting collagen formation and inducing lipogenic differentiation in lung fibroblasts.
While the exact mechanism of action is still being studied, metformin's influence on muscle fibrosis shows promising results for therapeutic uses, particularly in the elderly or those with muscle disuse atrophy.
Muscles' Electric Spark: Voltage Generation Explained
You may want to see also
Explore related products
Metformin's interaction with senescent cells
Metformin is a common drug that has been used in diabetes treatment for over half a century. It has been found to have applications on a cellular level, particularly in targeting senescent cells, which are also known as "zombie-like cells". Senescent cells secrete factors associated with inflammation that may underlie fibrotic tissue, or the hardening and scarring of tissues.
Metformin's anti-senescent properties have been demonstrated through pre-clinical studies. In one study, 20 healthy older adults underwent a muscle biopsy and MRI before the intervention, which involved five days of bed rest. One group of 10 received Metformin, while the other 10 received a placebo during a two-week run-in period. After the bed rest, participants received another muscle biopsy and MRI, then ceased treatments. All patients completed a seven-day re-ambulation period followed by a final muscle biopsy. The results showed that participants who took Metformin had less muscle atrophy and less fibrosis or excessive collagen. Their muscles also showed fewer markers of cellular senescence.
Metformin has been found to inhibit the expression of genes coding for multiple inflammatory cytokines seen during cellular senescence. It also prevents the translocation of NF-κB to the nucleus and inhibits the phosphorylation of IκB and IKKα/β, events required for the activation of the NF-κB pathway. Metformin can also inhibit mitochondrial damage via an AMP-activated protein kinase-dependent pathway in neuronal cells. This is significant because functional and structural mitochondrial defects contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
Metformin has also been found to improve the senescence of renal tubular epithelial cells in a high-glucose state through E2F1. It reduces the degree of renal fibrosis, DNA damage, and cellular senescence in the DM group, as well as reducing the expression of E2F1.
Muscles in Motion: How App Technology Helps
You may want to see also
Frequently asked questions
Metformin, a common drug used to treat diabetes, has been found to have a negative effect on muscle health. It has been shown to induce muscle atrophy and trigger the loss of muscle mass and quality.
The exact mechanism of how metformin affects muscle is unclear. However, studies have shown that it impairs muscle function through the regulation of myostatin in skeletal muscle cells. Metformin also increases the expression of myostatin, a molecule that regulates muscle volume.
While metformin has been associated with muscle atrophy, some studies suggest that it may have potential benefits for muscle recovery. For example, it has been found to reduce fibrosis or excessive collagen buildup, which can improve muscle function. Additionally, metformin's anti-senescent properties may help protect muscle cells and improve recovery after periods of inactivity.
The negative impact of metformin on muscle health is particularly concerning as muscle atrophy and weakness are strong predictors of disease development and mortality. This is especially relevant for elderly individuals who are more susceptible to falls, hospitalizations, and chronic diseases due to muscle disuse.
